The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Prehospital Use of Magnesium Sulfate as Neuroprotection in Acute Stroke
Open accessAbstract
BACKGROUND: Magnesium sulfate is neuroprotective in preclinical models of stroke and has shown signals of potential efficacy with an acceptable safety profile when delivered early after stroke onset in humans. Delayed initiation of neuroprotective agents has hindered earlier phase 3 trials of neuroprotective agents. METHODS: We randomly assigned patients with suspected stroke to receive either intravenous magnesium sulfate or placebo, beginning within 2 hours after symptom onset. A loading dose was initiated by paramedics before the patient arrived at the hospital, and a 24-hour maintenance infusion was started on the patient's arrival at the hospital. The primary outcome was the degree of disability at 90 days, as measured by scores on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability). RESULTS: Among the 1700 enrolled patients (857 in the magnesium group and 843 in the placebo group), the mean (±SD) age was 69±13 years, 42.6% were women, and the mean pretreatment score on the Los Angeles Motor Scale of stroke severity (range, 0 to 10, with higher scores indicating greater motor deficits) was 3.7±1.3. The final diagnosis of the qualifying event was cerebral ischemia in 73.3% of patients, intracranial hemorrhage in 22.8%, and a stroke-mimicking condition in 3.9%. The median interval between the time the patient was last known to be free of stroke symptoms and the start of the study-drug infusion was 45 minutes (interquartile range, 35 to 62), and 74.3% of patients received the study-drug infusion within the first hour after symptom onset. There was no significant shift in the distribution of 90-day disability outcomes on the global modified Rankin scale between patients in the magnesium group and those in the placebo group (P=0.28 by the Cochran-Mantel-Haenszel test); mean scores at 90 days did not differ between the magnesium group and the placebo group (2.7 in each group, P=1.00). No significant between-group differences were noted with respect to mortality (15.4% in the magnesium group and 15.5% in the placebo group, P=0.95) or all serious adverse events. CONCLUSIONS: Prehospital initiation of magnesium sulfate therapy was safe and allowed the start of therapy within 2 hours after the onset of stroke symptoms, but it did not improve disability outcomes at 90 days. (Funded by the National Institute of Neurological Disorders and Stroke; FAST-MAG ClinicalTrials.gov number, NCT00059332.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Self-citationA Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Berkhemer, O. A., Fransen, P. S. S., Beumer, D., van den Berg, L. A., Lingsma, H. F., Yoo, A. J., Schonewille, W. J., Vos, J. A., Nederkoorn, P. J., Wermer, M. J. H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411587 · Cited by 6,657
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Hemphill, J. C., Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., Fung, G. L., Goldstein, J. N., Macdonald, R. L., Mitchell, P. H., et al. (2015) · Stroke · doi:10.1161/str.0000000000000069 · Cited by 3,994
Treatment Strategies for Acute Ischemic Stroke Caused by Carotid Artery Occlusion
Li, W., Yin, Q., Xu, G., & Liu, X. (2016) · Interventional Neurology · doi:10.1159/000445304 · Cited by 2,319
Morgenstern, L. B., Hemphill, J. C., Anderson, C., Becker, K., Broderick, J. P., Connolly, E. S., Greenberg, S. M., Huang, J. N., Macdonald, R. L., Messé, S. R., et al. (2010) · Stroke · doi:10.1161/str.0b013e3181ec611b · Cited by 1,496
1,026 Experimental treatments in acute stroke
O'Collins, V. E., Macleod, M. R., Donnan, G. A., Horky, L. L., van der Worp, B. H., & Howells, D. W. (2006) · Annals of Neurology · doi:10.1002/ana.20741 · Cited by 1,460
Saver, J. L., Jahan, R., Levy, E. I., Jovin, T. G., Baxter, B., Nogueira, R. G., Clark, W., Budzik, R., & Zaidat, O. O. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61384-1 · Cited by 1,302
Self-citationAdeoye, O., Hornung, R., Khatri, P., & Kleindorfer, D. (2011) · Stroke · doi:10.1161/strokeaha.110.612358 · Cited by 474
Kidwell, C. S., Starkman, S., Eckstein, M., Weems, K., & Saver, J. L. (2000) · Stroke · doi:10.1161/01.str.31.1.71 · Cited by 426
Self-citation
Cited by
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2018) · Stroke · doi:10.1161/str.0000000000000158 · Cited by 5,446
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
Jovin, T. G., Chamorro, A., Cobo, E., de Miquel, M. A., Molina, C. A., Rovira, A., San Román, L., Serena, J., Abilleira, S., Ribó, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503780 · Cited by 4,898
Chamorro, Á., Dirnagl, U., Urra, X., & Planas, A. M. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00114-9 · Cited by 1,198
Magnesium in Prevention and Therapy
Gröber, U., Schmidt, J., & Kisters, K. (2015) · Nutrients · doi:10.3390/nu7095388 · Cited by 1,061
Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications
Tuo, Q., Zhang, S., & Lei, P. (2022) · Medicinal Research Reviews · doi:10.1002/med.21817 · Cited by 728
Magnesium and Human Health: Perspectives and Research Directions
Al Alawi, A. M., Majoni, S. W., & Falhammar, H. (2018) · International Journal of Endocrinology · doi:10.1155/2018/9041694 · Cited by 472
The Role of Magnesium in Neurological Disorders
Kirkland, A. E., Sarlo, G. L., & Holton, K. F. (2018) · Nutrients · doi:10.3390/nu10060730 · Cited by 382
“reviewed studies that demonstrate how magnesium sulfate has been found to improve scores on different measurement indices [196,201,207], neuroprotective properties [208,209], hospital stay length [207,210], and recovery outcomes [206,207].”
BackgroundAcute ischemic stroke therapy overview
Catanese, L., Tarsia, J., & Fisher, M. (2017) · Circulation Research · doi:10.1161/circresaha.116.309278 · Cited by 341
Metabotropic NMDA receptor signaling couples Src family kinases to pannexin-1 during excitotoxicity
Weilinger, N. L., Lohman, A. W., Rakai, B. D., Ma, E. M. M., Bialecki, J., Maslieieva, V., Rilea, T., Bandet, M. V., Ikuta, N. T., Scott, L., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4236 · Cited by 266
Xu, J., Wang, A., Meng, X., Yalkun, G., Xu, A., Gao, Z., Chen, H., Ji, Y., Xu, J., Geng, D., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.031197 · Cited by 261
Thomas Willis Lecture: Is Translational Stroke Research Broken, and if So, How Can We Fix It?
Dirnagl, U. (2016) · Stroke · doi:10.1161/strokeaha.116.013244 · Cited by 61
Sanossian, N., Rosenberg, L., Liebeskind, D. S., Starkman, S., Eckstein, M., Stratton, S., Pratt, F. D., Hamilton, S., Kim-Tenser, M., Sharma, L. K., et al. (2017) · Stroke · doi:10.1161/strokeaha.117.014745 · Cited by 21
Self-citation
Metadata
- Authors
- Saver, J. L., Starkman, S., Eckstein, M., Stratton, S. J., Pratt, F. D., Hamilton, S., Conwit, R., Liebeskind, D. S., Sung, G., Kramer, I., Moreau, G., Goldweber, R., & Sanossian, N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-05
- Volume
- 372
- Issue
- 6
- Pages
- 528-536
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168109100
- Cited by
- 407
- References
- 25
- FWCI
- 36.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.